[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 2,200
Citations 0
Correction
September 1, 2015

Clarification About Lower-Cost Drug

JAMA. 2015;314(9):952. doi:10.1001/jama.2015.9906

In the Capitol Health Call article entitled “Senator Urges VA to Nullify Patents for High-Cost Hepatitis C Drugs,” published in the July 14, 2015, issue of JAMA,1 the proposal for providing patented hepatitis C medication at a lower cost was unclear. In his letter, Sen Bernie Sanders (I, Vt) mentioned a legal statute that, rather than invalidate or nullify the patent, would allow Gilead to seek reimbursement from the Department of Veterans Affairs should they enlist third parties to manufacture the drug Solvadi (sofusbuvir) to make the drug less expensive for veterans infected with hepatitis C. This article and its title were corrected online.

References
1.
Buchholz  L.  Senator urges VA to nullify patents for high-cost hepatitis C drugs. JAMA. 2015;314(2):115.
×